AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient ...

AstraZeneca has reported a jump in quarterly sales thanks to record growth in its all-important US business, as the UK’s biggest drugmaker prepares to invest billions in the market ahead of potential ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

SINGAPORE] Asia-Pacific could be the new frontier for biotechnology investment, a report by consulting firm Bain & Company ...

CNBC's Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the company's most recent quarter, investment in innovation in the U.S., whether tariffs could impact prices, and much more.

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...